Proxy Votes Now

Home › Upcoming votes › Sunshine Biopharma Inc.

Sunshine Biopharma Inc. Annual Meeting December 29, 2026: What's on the Ballot

Prior-year votes at Sunshine Biopharma Inc. → 2023-2024 season, in the search

Read the proxy statement on EDGAR

Proxy summary

Summary, checked against the proxy statement. Each point is backed by a passage of the filing, shown under the point; figures under “Last year’s votes” come from the company’s Form 8-K. Read the proxy statement before relying on it.

Annual meeting held online: election of five directors, auditor ratification and an amendment to raise the equity incentive plan's share authorization.

Key points

What changed from last year

What’s on the ballot

Ballot read from the proxy statement and checked. As listed in Sunshine Biopharma Inc.’s proxy statement, with the board’s recommendation on each item. The company has filed 1 set of additional materials since; they can add to or change what is below, so check them before relying on it.

#ItemProposed byBoard recommendsLast year (same kind of item)
1 Election of Directors
Director election
Board For 5 nominees; support 99.9% to 99.9%
2 Ratification of M&K CPAS, PLLC as Our Independent Registered Public Accounting Firm
Auditor
Board For 99.9% support
3 Amendment to 2023 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder to 7,000,000 Board For —

Last year’s official results

From Sunshine Biopharma Inc.’s Form 8-K, filed December 12, 2025, for the meeting held December 11, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.

ItemSupport (of votes cast)Reported outcome
Elect Director: Dr. Steve N. Slilaty99.9%—
Elect Director: Mr. Camille Sebaaly99.9%Elected
Elect Director: Dr. Rabi Kiderchah99.9%Elected
Elect Director: Mr. David Natan99.9%Elected
Elect Director: Dr. Andrew Keller99.9%Elected
(ii) Ratification of the board of directors' appointment of M&K CPAS, PLLC as the Company's independent registered public accounting firm fo99.9%—
(iii) Approval of an amendment to the Company's 2023 Equity Incentive Plan to increase the number of shares of common stock authorized for i99.8%—

Filings for this meeting

About this page

The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.